BFA
CADX

BlackRock Fund Advisors’s CADENCE PHARMACEUTICALS, INC COM STK CADX Stock Holding History

BlackRock Fund Advisors’s Portfolio CADX Stock Details CADX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-3,126,305
Closed -$28.3M – 3872
2013
Q4 		$28.3M Buy
3,126,305
+438,821
+16% +$3.17M 0.01% 1777
2013
Q3 		$16.9M Buy
2,687,484
+357,064
+15% +$2.27M 0.01% 2055
2013
Q2 		$15.9M Buy
+2,330,420
New +$16.2M 0.01% 1984

Other funds holding CADX

OP
Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BlackRock Fund Advisors's CADX Position: Q1 2014 in Review

BlackRock Fund Advisors sold out of CADENCE PHARMACEUTICALS, INC COM STK (CADX) in Q1 2014, closing a stake of 3,126,305 shares — an estimated $28.3M sold.

BlackRock Fund Advisors first reported a position in CADX in Q2 2013 and held it in 3 quarters. The position peaked at $28.3M in Q4 2013. 3 funds tracked by Wall St. Rank hold CADX as of Q1 2014.

  • BlackRock Fund Advisors reported no remaining CADENCE PHARMACEUTICALS, INC COM STK position as of Q1 2014 after selling out during the quarter.
  • BlackRock Fund Advisors sold 3,126,305 CADENCE PHARMACEUTICALS, INC COM STK shares in Q1 2014, an estimated $28.3M.
  • BlackRock Fund Advisors first reported a position in CADENCE PHARMACEUTICALS, INC COM STK in Q2 2013 and held it in 3 quarters.
  • BlackRock Fund Advisors's CADENCE PHARMACEUTICALS, INC COM STK position peaked at $28.3M in Q4 2013.
  • 3 funds tracked by Wall St. Rank held CADENCE PHARMACEUTICALS, INC COM STK as of Q1 2014.

Based on BlackRock Fund Advisors's 13F filing for Q1 2014, filed 2 May 2014.